Well diffusion for antifungal susceptibility testing.

INTRODUCTION The increasing clinical and microbiologic resistance of Candida spp. isolates to several antifungal agents is becoming a serious problem. It is now reasonable to propose the use of antifungal susceptibility testing in Candida spp. isolates from patients who have failed conventional therapy, before the selection of an empirical therapy. METHODS One hundred and fifty eight isolates of Candida spp. were evaluated simultaneously by broth microdilution (NCCLS standard) and well diffusion testing (WD), a diffusion method similar to disc diffusion. RESULTS According to the Wilcoxon Signed Ranks test performed, there was no significant difference (p>0.05) between both methodologies for all antifungal agents tested (fluconazole, itraconazole, posaconazole, caspofungin and amphotericin B, with C. tropicalis, C. krusei, C. dubliniensis, C. guillermondii, C. parapsilosis, C. albicans and C. glabrata). A significant difference was observed when comparing well diffusion with NCCLS for fluconazole WD 80% (p=0.008) in C. glabrata, as well as WD 80% (p=0.002) and WD 50% (p=0.002) in C. albicans. CONCLUSIONS The well diffusion test is simple, easy to reproduce, inexpensive, easy both to read and interpret, and has a good correlation to the reference NCCLS microdilution test and may represent an alternative method for antifungal drug susceptibility testing of Candida spp., mainly in laboratories with few resources.

[1]  M. Piens,et al.  Fluconazole susceptibility of Candida isolates from oropharyngeal candidosis , 1997, Mycoses.

[2]  J. Rex,et al.  Antifungal susceptibility testing: technical advances and potential clinical applications. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  J. Martínez-Suárez,et al.  Standardization of antifungal susceptibility testing and clinical relevance. , 1998, Medical mycology.

[4]  L. Deibis,et al.  In Vitro susceptibility of 137 Candida sp. Isolates from HIV positive patients to several antifungal drugs , 2004, Mycopathologia.

[5]  M. Klepser Antifungal Resistance Among Candida Species , 2001, Pharmacotherapy.

[6]  J. Vazquez,et al.  In vitro antifungal susceptibility methods and clinical implications of antifungal resistance. , 2000, Medical mycology.

[7]  M. Pfaller,et al.  Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  M. Ghannoum,et al.  Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Labora , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  M. Feo The ‘nascent culture’ and its use , 1978, Mycopathologia.

[10]  A. Sierra,et al.  In vitro susceptibility of 545 isolates of Candida spp. to four antifungal agents , 1994, Mycoses.

[11]  E. Anaissie,et al.  Importance of Candida species other than Candida albicans as opportunistic pathogens. , 1998, Medical mycology.

[12]  M. Trautmann,et al.  Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection , 1994, Journal of clinical microbiology.

[13]  C B Moore,et al.  High incidence of antifungal drug resistance in Candida tropicalis. , 1996, International journal of antimicrobial agents.

[14]  E. Bruck,et al.  National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.